Results of the International Psychiatric Genomics Consortium unveiled
TORONTO – Canadian and international scientists have uncovered six new schizophrenia risk genes in the largest study of its kind. The results of the international Psychiatric Genomics Consortium CNV working group are published in the Nov. 21 advance online edition of Nature Genetics
, and further support the important role genes play in susceptibility to schizophrenia, and may be helpful in early diagnosis.
Scientists at the University of British Columbia have genetically engineered a mouse that does not become addicted to cocaine, adding to the evidence that habitual drug use is more a matter of genetics and biochemistry than just poor judgment.
The mice they created had higher levels of a protein called cadherin, which helps bind cells together. In the brain, cadherin helps strengthen synapses between neurons – the gaps that electrical impulses must traverse to bring about any action or function controlled by the brain, whether it’s breathing, walking, learning a new task or recalling a memory.
Research determines how the brain recognizes what’s important at first glance.
Researchers at the Centre for Neuroscience Studies (CNS) at Queen’s University have discovered that a region of the brain – the superior colliculus – contains a mechanism responsible for interpreting how visual input from a scene determines where we look. This mechanism, known as a visual salience map, allows the brain to quickly identify and act on the most important information in the visual field, and is a basic mechanism for our everyday vision.
Scientists identify mechanism for brain dysfunction following seizures and drugs that prevent this impairment from occurring.
Six years ago, Cam Teskey, PhD, decided to follow a hunch. Armed with an advanced new tool designed to measure oxygen levels in tissues, he wanted to look at the brains of rats to see what was happening during seizures.
Dr. Robert Zatorre
Have you ever met someone who just wasn’t into music? They may have a condition called specific musical anhedonia, which affects three-to-five per cent of the population.
Researchers at the University of Barcelona and the Montreal Neurological Institute and Hospital of McGill University have discovered that people with this condition showed reduced functional connectivity between cortical regions responsible for processing sound and subcortical regions related to reward.
Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.